Download For ranolazine study

Short Summary
Title: “Efficiency of ranolazine in obstructive coronary artery disease with left
ventricular dysfunction”
Aim:
Ranolazine is provided efficiency of anti-ischemic/antianginal properties in patients
with chronic angina without clinically significant changes in heart rate or blood
pressure. Now we want to see the efficiency of ranolazine in obstructive coronary
artery disease with left ventricular dysfunction.
Material and methods
Inclusion criteria:
Obstructive coronary artery disease patients with echocardiogram wise having left
ventricular dysfunction of ejection fraction of <40% with normal QT on ECG
a. chronic stable angina
b. b. acute coronary syndrome
Exclusion criteria:
Patients who have underlying QT prolongation on ECG or in Frank clinical congestive
cardiac failure in class 4 or known allergy to this drug.
Dose and method of administration:
Starting dose of ranolazine 500mg twice daily to increased further to 1000mg
twice daily and for three months.
Number of patients to be recruited: 100
Details of cardiac complaint, past history of cardiac interventions will be noted. On day
1 and at 3 months functional status in addition to clinical functional status will be
evaluated with modified Bruce or classical Bruce protocol of treadmill. All biochemical
parameters required for CAD including ECG, 2D-echocardiogram will be done on day of
recruitment and at 3 months.. In hospital, at one month events of recurrence of angina or
myocardial infarction, palpitation degree of breathlessness will be assed.